Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions

30 Dec 2016

Abstract excerpt

// Mohammad Alzrigat 1 , Alba Atienza Párraga 1, * , Prasoon Agarwal 2, * , Hadil Zureigat 3 , Anders Österborg 4 , Hareth Nahi 5 , Anqi Ma 6 , Jian Jin 6 , Kenneth Nilsson 1 , Fredrik Öberg 1 , Antonia Kalushkova 1 , Helena Jernberg-Wiklund 1 1 Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden 2 Department of Laboratory...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28052011
DOI: 10.18632/oncotarget.14378

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functionsPMID 28052011Read ↗

[EZH2 is therapeutic target for personalized treatment in multiple myeloma].Semantic proximity Read ↗

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.Semantic proximity Read ↗

Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic targetSemantic proximity Read ↗

The Role of Epigenetics in the Development and Progression of Multiple MyelomaSemantic proximity Read ↗

Roles of miRNA dysregulation in the pathogenesis of multiple myelomaSemantic proximity Read ↗

MiRNA as a Potential Target for Multiple Myeloma Therapy–Current Knowledge and PerspectivesSemantic proximity Read ↗

Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic ModificationsSemantic proximity Read ↗

The biological significance of histone modifiers in multiple myeloma: clinical applicationsSemantic proximity Read ↗

Epigenetic Aberrations in Multiple MyelomaSemantic proximity Read ↗

Role of epigenetics-microRNA axis in drug resistance of multiple myelomaSemantic proximity Read ↗

MicroRNAs in the Pathobiology of Multiple MyelomaSemantic proximity Read ↗

Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectivesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.